Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYK vs BDX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BDX Captures Overall Composite Edge (33.7 SELL vs 46.5 HOLD), While SYK Leads 4–2 on Growth & Valuation Pillars

BDX Overall Winner 6-Pillar Tally: SYK 4 – 2 BDX Matrix Metrics: SYK 7 – 3 BDX

As of Nov 16, 2026, Becton, Dickinson and Co. (BDX) captures the overall head-to-head institutional edge over Stryker Corporation (SYK) on higher Unified Composite conviction (33.7/100 SELL vs. 46.5/100 HOLD) after splitting the core matrix 3–7 (led by Valuation Multiples, Options & Positioning), while SYK wins 4–2 across the 6-pillar growth and valuation breakdown. SYK trades at $310.79 (19.0x Forward P/E, 24.0% operating margin) versus BDX at $216.52 (16.4x Forward P/E, 15.7% operating margin).

  • Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. BDX 33.7/100 SELL), BDX captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (15.7% vs. 24.0% operating margin) and revenue trajectory (-10.5% vs. +7.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYK vs BDX
SYK NYSE
Stryker Corporation
Surgical & Medical Instruments & Apparatus
$310.79
+0.37% 1D
Market Cap $118.9B
TTM Revenue $26.3B
Forward P/E 19.0x
Beta / 30D Vol 0.22β · 50% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 37.0 Fund 49.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $312.55 · SMA50: $292.40
BDX NYSE Head-to-Head Winner
Becton, Dickinson and Co.
Surgical & Medical Instruments & Apparatus
$216.52
-0.69% 1D
Market Cap $58.8B
TTM Revenue $19.5B
Forward P/E 16.4x
Beta / 30D Vol 0.16β · 25% Vol
Unified Composite Score
33.7 / 100 SELL
Tech 5.0 Fund 34.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.0% over 20 days), RSI 75
RSI-14: 75.4 · SMA20: $204.79 · SMA50: $191.60

6-Pillar Scorecard Institutional Category Breakdown (SYK 4 – 2 BDX)

Columns: Metric · SYK · BDX
1. Valuation Multiples BDX
Forward P/E 19.0x 16.4x
Trailing P/E 33.3x 42.6x
PEG Ratio 1.54x 0.99x
EV / Revenue 5.0x 4.2x
2. Growth & Scale SYK
Revenue Growth (YoY) +7.6% -10.5%
Earnings Growth (YoY) -11.7% +47.6%
TTM Revenue (USD) $26.3B $19.5B
Market Cap $118.9B $58.8B
3. Profitability & Quality SYK
Gross Margin 65.7% 47.0%
Operating Margin 24.0% 15.7%
Net Profit Margin 13.8% 5.9%
Return on Equity (ROE) 16.0% 5.7%
4. Balance Sheet & Cash Flow SYK
Cash Generation (TTM) $4.57B $3.71B
Cash Flow Margin 17.4% 19.1%
Net Cash / Leverage $11.7B Net Debt (0.64x D/E) $23.6B Net Debt (0.69x D/E)
Dividend Yield 1.10% None (0.00%)
5. Options & Positioning BDX
Options Structure Phase SURGE BREAKOUT
Current IV / %ile 28.1% (5th %ile) 20.7% (7th %ile)
Put/Call OI Skew 0.30x (Call-Skewed) 0.12x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat SYK
OpEx & R&D Intensity 41.7% of Rev ($11.0B) 31.3% of Rev ($6.09B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYK (7) vs BDX (3)
Institutional Metric SYK BDX Criterion Row Edge
Market Capitalization
Scale
$118.9B $58.8B Larger Scale SYK
Trailing P/E Ratio
Valuation
33.3x 42.6x Lower Multiple SYK
Forward P/E Ratio
Valuation
19.0x 16.4x Lower Multiple BDX
Revenue Growth (YoY)
Growth
+7.6% -10.5% Higher Growth SYK
Operating Margin (TTM)
Profitability
24.0% 15.7% Higher Margin SYK
Net Profit Margin
Profitability
13.8% 5.9% Higher Margin SYK
Return on Equity (ROE)
Capital Efficiency
16.0% 5.7% Higher ROE SYK
52-Week Range Position
Momentum
36% ($267–$389) 95% ($140–$220) Stronger Trend BDX
Beta / 30D Volatility
Risk Regime
0.22β · 50% Vol 0.16β · 25% Vol Lower Realized Risk BDX
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD) 33.7 / 100 (SELL) Higher Composite SYK
Trailing 12M Revenue (USD)
Operating Scale
$26.3B $19.5B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.7% 47.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.54x PEG · 5.0x EV/Rev 0.99x PEG · 4.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$4.57B ($11.7B Net Debt (0.64x D/E)) $3.71B ($23.6B Net Debt (0.69x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BDX +7.45 pp
SYK: +5.47% · BDX: +12.92%
3M Horizon BDX +25.99 pp
SYK: -6.21% · BDX: +19.78%
6M Horizon BDX +52.89 pp
SYK: -0.78% · BDX: +52.11%
1Y Horizon BDX +28.93 pp
SYK: -16.77% · BDX: +12.16%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SYK Revenue BDX Revenue SYK Op. Margin BDX Op. Margin Margin Leader
FY2018 $13.6B $16.0B 18.7% 9.4% SYK
FY2019 $14.9B $17.3B 18.2% 10.2% SYK
FY2020 $14.3B $16.1B 15.5% 5.7% SYK
FY2021 $17.1B $19.1B 15.1% 11.8% SYK
FY2022 $18.4B $18.9B 15.4% 12.1% SYK
FY2023 $20.5B $19.4B 19.0% 10.9% SYK
FY2024 $22.6B $20.2B 16.3% 11.9% SYK
FY2025 $25.1B $21.8B 19.5% 11.8% SYK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYK SURGE
8d in phase · OBV DISTRIBUTION
Current IV 28.1%
IV Percentile 5th %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BDX BREAKOUT
60d in phase · OBV ACCUMULATION
Current IV 20.7%
IV Percentile 7th %ile
Put/Call OI Skew 0.12x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact BDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYK Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($11.0B)
90D Engineering Disclosures 0 Published · Surgical Robotics
BDX Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $58.8B market capitalization and 15.7% operating margin.
OpEx & R&D Reinvestment 31.3% of Rev ($6.09B)
90D Engineering Disclosures 0 Published

Investor FAQ SYK vs BDX Key Questions & Quantitative Answers

As of Nov 16, 2026, Becton, Dickinson and Co. (BDX) captures the overall head-to-head institutional edge over Stryker Corporation (SYK) on higher Unified Composite conviction (33.7/100 SELL vs. 46.5/100 HOLD) after splitting the core matrix 3–7 (led by Valuation Multiples, Options & Positioning), while SYK wins 4–2 across the 6-pillar growth and valuation breakdown. SYK trades at $310.79 (19.0x Forward P/E, 24.0% operating margin) versus BDX at $216.52 (16.4x Forward P/E, 15.7% operating margin). Composite vs. Pillar Nuance: While SYK currently prints a higher short-term Unified Composite Score (46.5/100 HOLD vs. BDX 33.7/100 SELL), BDX captures the overall institutional head-to-head verdict (3–7 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (15.7% vs. 24.0% operating margin) and revenue trajectory (-10.5% vs. +7.6% YoY).

SYK leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with BDX at -10.5% YoY revenue growth and +47.6% YoY earnings growth on $19.5B TTM revenue (47.0% gross margin, 15.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SYK cumulative revenue shifted +84.7% while BDX shifted +36.7%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 31.3% of Rev ($6.09B) (0 disclosures) for BDX.

BDX screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas BDX trades at 16.4x Forward P/E, 42.6x Trailing P/E, 0.99x PEG, and 4.2x EV/Revenue (19.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus BDX (5.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, BDX carries 20.7% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.12x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.16β · 25% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.